Benzinga | Aug 10, 2021 07:16AM EDT

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

-- IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated

-- Continued Advancement of Broad Therapeutic Pipeline that Includes Protein Degraders, Enzymatic Inhibitors and Transcription Factor Disruptors Targeting the Chromatin Regulatory System